SEPN News
Archived Headlines
- GPCR-focused biotech Septerna prices further upsized IPO at $18 10/25/24
- GPCR-focused biotech Septerna ups proposed deal size by 57% ahead of $275 million IPO 10/24/24
- GPCR-focused biotech Septerna sets terms for $175 million IPO 10/21/24
- US IPO Week Ahead: Ingram Micro set to return to public markets in week’s largest IPO 10/18/24
- GPCR-focused biotech Septerna files for a $100 million IPO 10/02/24
Biotech IPOs are back: Why 2026 could mark a hot year for the sector
After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially. ...read more
Renaissance Capital’s October IPO Market Update
Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election. ...read more
US IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies. One scheduled deal did not get done (PRB). Tech distributor Ingram Micro (INGM) priced slightly above the midpoint to raise $409 million at a $5.3...read more